Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Aug;105(2):138-147.
doi: 10.1111/ejh.13417. Epub 2020 Jun 16.

Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols

Marta Sitges  1   2 , Blanca Boluda  3 , Ana Garrido  4 , Mireia Morgades  1 , Isabel Granada  1 , Eva Barragan  3 , Montserrat Arnan  5 , Josefina Serrano  6 , Mar Tormo  7 , Juan Miguel Bergua  8 , Mercedes Colorado  9 , Olga Salamero  10 , Jordi Esteve  11 , Celina Benavente  12 , Manuel Pérez-Encinas  13 , Rosa Coll  2 , Josep-Maria Martí-Tutusaus  14 , Salut Brunet  4 , Jorge Sierra  4 , Miguel Ángel Sanz  3 , Pau Montesinos  3 , Josep-Maria Ribera  1 , Susana Vives  1 ; PETHEMA, CETLAM cooperative groups
Collaborators, Affiliations
Multicenter Study

Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols

Marta Sitges et al. Eur J Haematol. 2020 Aug.

Abstract

Introduction: Inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2) is a rare poor prognosis cytogenetic abnormality present in acute myeloid leukemia (AML) and other myeloid neoplasms.

Objective: The aim of this study was to evaluate the outcome of a cohort of 61 patients with newly diagnosed AML with inv(3)/t(3;3) treated with homogeneous intensive chemotherapy protocols conducted by the Spanish PETHEMA and CETLAM cooperative groups between 1999 and 2017.

Methods: In this retrospective study the main clinical and biologic parameters were collected. The complete response (CR) rate, the cumulative incidence of relapse (CIR) and the overall survival (OS) were calculated. An analysis of prognostic factors for survival was performed.

Results: Sixty-one patients received induction and only 18 (29%) achieved CR (median age, 46 years). Allogeneic hematopoietic stem cell transplantation (alloHSCT) was performed in 36 patients (59%), 15 with active disease. One- and 4-year CIR were 52% and 56%. One- and 4-year OS probabilities were 41% and 13%. By multivariate analysis monosomal karyotype (MK) was associated with poorer OS (HR 2.0, P = .017).

Conclusion: Inv(3)/t(3;3) AML is a poor prognosis entity with low response to standard chemotherapy and to alloHSCT because of frequent and early relapse. MK was associated with a poorer prognosis. Improved therapeutic strategies are clearly needed.

Keywords: acute myeloid leukemia; bone marrow transplantation; molecular cytogenetics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Arber DA, Vardiamn JW, Brunning RD, et al. Acute myeloid leukemia with inv(3)(q21.3q26.2) or t(3;3)(q21,3;q26.2); RPN1-EVI1. In: Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, Thiele JVJ, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th ed) Lyon: IARC Press; 2008: 110-118.
    1. Arber DA, Brunning RD, Le Beau MM, et al. Acute myeloid leukemia with inv(3)(q21.3q26.2) or t(3;3)(q21,3;q26.2);GATA2, MECOM. In: Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi ASR, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2017. p. 138-9.
    1. Gröschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1and GATA2 deregulation in leukemia. Cell. 2014;157:369-381.
    1. Yamazaki H, Suzuki M, Otsuki A, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cel. 2014;25:415-427.
    1. Creutzig U, Zimmermann M, Reinhardt D, et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer. 2016;122:3821-3830.

Publication types

MeSH terms

LinkOut - more resources